Results 61 to 70 of about 459 (131)

Potent and Sustained Lowering of Serum Uric Acid by YJH‐012‐D, a GalNAc‐Conjugated siRNA Targeting Xanthine Dehydrogenase

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
We developed a GalNAc‐conjugated siRNA targeting hepatic XDH, which effectively reduces uric acid production by silencing XDH expression, offering a promising therapeutic approach for hyperuricemia. ABSTRACT Hyperuricemia (HUA) is primarily driven by hepatic overproduction of urate, mediated by xanthine dehydrogenase (XDH).
Tingke Tang   +12 more
wiley   +1 more source

The Reality of Active Targeting in Nanomedicine: Promise Versus Performance

open access: yesChemBioChem, Volume 27, Issue 14, 29 July 2026.
Schematic representation of a multi‐functional nanocarrier decorated with diverse ligands. Ligand type, density and spatial organisation collectively determine targeting behaviour, highlighting the complexity of active targeting beyond simple ligand–receptor interactions.
Francesco Cellesi
wiley   +1 more source

Histochemical detection of sugar residues in lizard teeth (Liolaemus gravenhorsti): a lectin-binding study

open access: yesBiological Research, 2000
The structural diversity of the many oligosaccharide chains of surface glycoconjugates renders them likely candidates for modulators of cell-interactions, cellular movements, differentiation, and cellular recognition. A selection of different lectins was
MARCELA FUENZALIDA   +5 more
doaj  

Preparation of radiolabeled GM2 and GA2 gangliosides.

open access: yesJournal of Lipid Research, 1979
GM2 and GA2 gangliosides from the brain of a patient who died of Sandhoff's disease were purified by solvent partition, silicic acid and silica gel column chromatography, and silica gel preparative thin-layer chromatography.
A Novak   +3 more
doaj   +1 more source

Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib

open access: yesDrug Design, Development and Therapy, 2018
Wendu Duan, Yan Liu Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, Baoding, Hebei Province 071000, People’s Republic of China Purpose: Targeted hepatocellular carcinoma therapy was carried out to improve the ...
Duan W, Liu Y
doaj  

A Novel Pot-Economy Approach to the Synthesis of Triantennary GalNAc-Oligonucleotide

open access: yesMolecules
N-Acetylgalactosamine (GalNAc) is an efficient and multifunctional delivery tool in the development and synthesis of chemically modified oligonucleotide therapeutics (conjugates).
Artem Evgenievich Gusev   +6 more
doaj   +1 more source

Presence of N-acetylgalactosamine/galactose residues on bronchioloalveolar cells during rat postnatal development

open access: yesEuropean Journal of Histochemistry, 2019
In mammals, the alveolarization process develops predominantly after birth. Airway cells display a complex assemblage of glycans on their surface. These glycans, particularly terminal glycan extensions, are important effective carriers of information ...
Maria de Fátima Martins   +2 more
doaj   +1 more source

Lectin Histochemical Study of Cell Surface Glycoconjugate in Gastric Carcinoma Using Helix Pomatia Agglutinin [PDF]

open access: yesActa Medica Iranica, 2010
"nAltered glycosylation of proteins in cancer cells is one of the main processes responsible for anaplasia, invasion and metastatic potential of neoplastic cells.
Mohammad Reza Arab   +3 more
doaj   +2 more sources

Overelaborated synaptic architecture and reduced synaptomatrix glycosylation in a Drosophila classic galactosemia disease model

open access: yesDisease Models & Mechanisms, 2014
Classic galactosemia (CG) is an autosomal recessive disorder resulting from loss of galactose-1-phosphate uridyltransferase (GALT), which catalyzes conversion of galactose-1-phosphate and uridine diphosphate (UDP)-glucose to glucose-1-phosphate and UDP ...
Patricia Jumbo-Lucioni   +2 more
doaj   +1 more source

Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics

open access: yesMolecular Therapy: Nucleic Acids, 2017
A main challenge in realizing the full potential of nucleic acid therapeutics is efficient delivery of them into targeted tissues and cells. N-acetylgalactosamine (GalNAc) is a well-defined liver-targeted moiety benefiting from its high affinity with ...
Yuanyu Huang
doaj   +1 more source

Home - About - Disclaimer - Privacy